| Schedule of Basic and Diluted Loss Per Share |
Basic and diluted loss per share for each of the periods presented were calculated as follows: | | | For the Six Months Ended June 30, | | | | | 2025 | | | 2026 | | | 2026 | | | | | RMB | | | RMB | | | US$ | | | Numerator: | | | | | | | | | | | Net loss | | | (19,885,492 | ) | | | (238,170,188 | ) | | | (35,101,942 | ) | | Accretion to redemption value of mezzanine equity | | | (52,405,735 | ) | | | — | | | | — | | | Less: Net loss attributable to noncontrolling interests | | | (960 | ) | | | (8,384,599 | ) | | | (1,235,737 | ) | | Net loss attributable to the Pomdoctor Limited’s ordinary shareholders | | | (72,290,267 | ) | | | (229,785,589 | ) | | | (33,866,205 | ) | | | | | | | | | | | | | | | | Denominator: | | | | | | | | | | | | | | Weighted average number of shares outstanding – basic | | | 6,310,198 | | | | 23,182,964 | | | | 23,182,964 | | | Weighted average number of shares outstanding – diluted | | | 6,310,198 | | | | 23,182,964 | | | | 23,182,964 | | | | | | | | | | | | | | | | | Loss per share – Basic: | | | (11.46 | ) | | | (9.91 | ) | | | (1.46 | ) | | | | | | | | | | | | | | | | Loss per share – Diluted: | | | (11.46 | ) | | | (9.91 | ) | | | (1.46 | ) |
|